amfAR, The Foundation for AIDS Research

Impact Grants: Gaining Insights from the Clinic

Funding Opportunities – Additional Information

All performance periods are to start October 1, 2018

Total costs include indirect costs at a 20% maximum 

Funding Opportunities

1.1: Meta-analysis of data from completed clinical trials (1 year; Total Costs: $100,000)

  • items D and E (see below) are required as applicable

Existing clinical trials are trials that are already fully funded (by amfAR or others) and have received all necessary institutional and regulatory approvals.

1.2: Addition of study arm to an existing clinical trial (4 years; Total Costs: $300,000)

  • items A, B, C, D and E (see below) are required

1.3: Addition of reservoir and outcome (PTC or delay to rebound) analyses to an existing clinical trial (4 years; Total Costs: $100,000)

  • items A, B, C, D and E (see below) are required

2.1: Addition of a recruitment and retention intervention to an existing clinical trial (4 years; Total Costs: $50,000)

  • must be conducted in the context of an existing curative clinical trial
  • must propose an intervention hypothesized to increase participant recruitment and retention over a control group included in the design
  • items A, B, C, D and E (see below) are required

2.2: Characterization of clinical case studies (1 year; Total Costs: $75,000)

  • must include case studies, outside the context of a clinical trial, of unexpected post-treatment control or delay-to-rebound outcomes
  • analyses of biological samples taken after, and ideally before, treatment interruption
  • amfAR can provide non-binding advice to physicians interested in finding academic collaborators. Such requests to amfAR must be made more than three weeks prior to the LOI receipt date deadline. (Email grants@amfar.org) If you are qualified to conduct cure research-relevant assays on clinical samples and wish to be included on amfAR’s list of potential academic collaborators, please contact amfAR at grants@amfar.org.
  • items D and E (see below) are required

2.3: Characterization of the reservoir in LMIC settings (2 years; Total Costs: $50,000)

  • principal investigators must be based in a LMIC setting
  • biological samples or study participants must be based in a LMIC setting
  • the majority of the funding should be allocated to activities in a LMIC setting. Qualifying low-, lower-middle- or upper-middle-income economy countries (LMIC) as defined by the World Bank.
  • study participants not readily available in HIC incl. e.g.: those with coinfections such as TB, helminths, etc.; treatment initiation at CD4<200; pediatric/adolescent; female
  • Items D and E (see below) are required

 

A. The Background and Rationale section of the research plan must include a description of the existing clinical trial and timeline. The study protocol may be provided as an addendum.  

The addenda must include

B. Documentation that the existing trial is already funded and that all necessary institutional (e.g., IRB) and regulatory (e.g., FDA or equivalent non-U.S. agency) approvals have been received.

C. Documentation that the trial investigators are willing and able, as applicable, to (1.2) add another study arm, (1.3) share samples, or (2.1) incorporate the proposed intervention.

D. Describe the procedure and provide a timeline for obtaining all necessary institutional approvals (e.g., IRB, IBC) required for the research proposed in the application. If the institutional approval(s) have already been obtained, include documentation.

E. Describe the procedure and provide a timeline for obtaining all necessary regulatory (e.g., FDA or equivalent non-U.S. agency) approvals required for the research proposed in the application. If the regulatory approvals have already been obtained, include documentation.

Funding will be rescinded if documentation items D and E are not submitted to amfAR within 3 months following the performance period start date.

 

Questions about the intended scope of this RFP may be sent to grants@amfar.org.  Phone calls will not be accepted.